|
KMID : 1033620190460020050
|
|
Clinical and Experimental Reproductive Medicine
2019 Volume.46 No. 2 p.50 ~ p.59
|
|
|
Clinical application of serum anti-Mullerian hormone in women
|
|
Oh So-Ra
Choe Sun-Yi
Cho Yeon-Jean
|
|
|
Abstract
|
|
|
|
Anti-Mullerian hormone (AMH), a peptide growth factor of the transforming growth factor-β family, is a reliable marker of ovarian reserve. Regarding assisted reproductive technology, AMH has been efficiently used as a marker to predict ovarian response to stimulation. The clinical use of AMH has recently been extended and emphasized. The uses of AMH as a predictive marker of menopause onset, diagnostic tool for polycystic ovary syndrome, and assessment of ovarian function before and after gynecologic surgeries or gonadotoxic agents such as chemotherapy have been investigated. Serum AMH levels can also be affected by environmental and genetic factors; thus, the effects of factors that may alter AMH test results should be considered. This review summarizes the findings of recent studies focusing on the clinical application of AMH and factors that influence the AMH level and opinions on the use of the AMH level to assess the probability of conception before reproductive life planning as a “fertility test.”
|
|
|
KEYWORD
|
|
|
Anti-Mullerian hormone, Fertility, Ovarian reserve, Polycystic ovary syndrome, Surgery
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|